Navigation Links
CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns Hopkins University School of Medicine
Date:11/6/2009

ational treatment."

The initiation of CEL-SCI's rapidly-accelerated LEAPS-H1N1 clinical development program builds on CEL-SCI's pioneering work with its LEAPS technology in the context of H1N1. CEL-SCI's L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) technology allows the Company to direct an immune response against specific disease epitopes. In the case of CEL-SCI's investigational LEAPS-H1N1 treatment, this involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu. This is intended to enable stimulation of the specifically-needed immune responses, while avoiding the administration of regions of H1N1, and other viruses, which may exacerbate the problem of cytokine storm, which CEL-SCI scientists believe may be involved in the death of some H1N1 patients.

L.E.A.P.S. technology is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize, non-recombinantly, proprietary immunogens. The L.E.A.P.S. technology combines a small peptide that activates the immune system with a small peptide from a disease-related protein, such as the H1N1 hemagglutinin molecule, to make an investigational product that induces defined immune responses. Each L.E.A.P.S. construct is composed of a T cell binding ligand (TCBL) which previously has demonstrated the ability to induce and elicit protective immunity and antigen-specific antibody production in animal models. Thus, extensive animal studies conducted to date indicate that any disease for which an antigenic sequence has been identified, such as infectious, parasitic, malignant or autoimmune diseases and allergies, are potential therapeutic or preventive sites for the application of L.E.A.P.S. technology.

About CEL-SCI Corporation

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine® which is being readied for a global Phase III trial in advanced primary he
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. CEL-SCI Presents Data at American College of Rheumatology Conference Which Suggests that CEL-2000 Has Potential to Slow Damage Caused by Rheumatoid Arthritis
2. CEL-SCI Corporation to Raise $20 Million in Registered Direct Offering
3. CEL-SCI Corporation Announces Elimination of $8.3 Million Convertible Notes
4. CEL-SCI Completes $5.85 Million Registered Direct Offering
5. CEL-SCI Scientist Invited to Discuss Plans to Launch Unique Manufacturing Process That Saves Cost While Enhancing the Shelf Life of Drugs at 5th Annual Aseptic Processing of Sterile Drug Products Conference
6. CEL-SCI Expands Testing of Its Vaccine to Determine Efficacy Against More Virulent Strain of H1N1 Swine and Other Influenza Viruses
7. CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results
8. CEL-SCI Announces Exclusive Licensing Agreement for Cancer Drug Multikine(R) for Republic of South Africa
9. CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine
10. CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference
11. CEL-SCI Corporation Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... have to be at least 2 years old to ... no official U.S. guidance exists other than the general ... breastfeed for at least the first six months. , ... That,s the question that motivated researchers at the University ... study the eating patterns of American infants at 6 ...
(Date:10/30/2014)... 2014 Nutrition Leaders, a popular online ... aids, and more, is currently hosting a sweepstakes on ... underway, is open to U.S. residents age 18 and ... 2014. One lucky winner will then be selected at ... gift card to NutritionLeaders.com. , Nutrition Leaders’ managing director ...
(Date:10/30/2014)... Burlington, NC (PRWEB) October 30, 2014 ... life, commercial, and health insurance plans for North Carolina ... its satellite office in Burlington’s Holly Hill Mall. The ... 15, with agents already helping customers through all facets ... policy purchase. , Allred Insurance spokesman Scott Allred couldn’t ...
(Date:10/30/2014)... PreDiabetes Centers , the pioneer in prediabetes ... a supply of sugardown®, a chewable dietary supplement that ... spikes. Learning how to control blood sugar levels and ... diabetes prevention plan. , Shoppers who spend $50 or ... sugardown. The offer expires November 30. , Full-size ...
(Date:10/30/2014)... Steven Reinberg HealthDay Reporter , ... to men with prostate cancer who also have certain heart ... cause, a new study suggests. , , The therapy in question ... cancer to reduce levels of male hormones to prevent the ... the current research, this hormone therapy was linked to triple ...
Breaking Medicine News(10 mins):Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 2Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 3Health News:Nutrition Leaders Announces Gift Card Sweepstakes 2Health News:Allred Insurance Satellite Office Grand Opening 2Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3
... social science research organization NORC at the University of Chicago contradicts ... above age 80. It also explains why there ... and above than the Census Bureau predicted there would be as ... a new way of accurately measuring mortality of Americans who are ...
... at NYU Langone Medical Center will present their latest ... tendon, bone and joint at the annual meeting of ... in San Francisco, California. "The introduction ... in clinical care, allows our researchers to identify the ...
... a way to study how our brains assess the behavior ... Their study, described in a paper in the ... to use a computational approach to tease out differing patterns of ... compete against each other in a game, they try to make ...
... At a time when there is tremendous concern about ... and the costs of technology, the Canadian Institutes of ... to improve end of life decision making amongst seriously ... receiving funding for this initiative. , "Canada,s aging population ...
... Institutet, has received a grant of 1.6 million Euro ... the fundamental causes of diabetes. The grant will make ... the release of insulin is regulated in living organisms ... more effective drugs against diabetes. , Diabetes is an ...
... a few years, a new generation of easy-to-use blood-thinning drugs ... are at risk for stroke, according to a journal article ... new drugs do not require patients to come in to ... Nor do the drugs require extensive dietary restrictions. , First ...
Cached Medicine News:Health News:Odds of living a very long life lower than formerly predicted 2Health News:Odds of living a very long life lower than formerly predicted 3Health News:NYU Langone orthopaedic experts present research, clinical advances at AAOS meeting 2Health News:NYU Langone orthopaedic experts present research, clinical advances at AAOS meeting 3Health News:NYU Langone orthopaedic experts present research, clinical advances at AAOS meeting 4Health News:It's not solitaire: Brain activity differs when one plays against others 2Health News:CIHR invests in Queen's-led study on end-of-life decision making 2Health News:Donation opens new opportunities for more effective diabetes treatment 2Health News:Easy-to-use blood thinners likely to replace Coumadin 2
(Date:10/30/2014)... , Oct. 30, 2014   ViaDerma, ... devoted to bringing new products to market, has ... called TetraStem. TetraStem is a topical liquid tetracycline-based ... system that can convert oral medication active ingredients ... as a first aid antibiotic to help prevent ...
(Date:10/30/2014)... 2014 China Biologic Products, Inc. (NASDAQ: CBPO, ... plasma-based biopharmaceutical company in China , ... quarter 2014 financial results on Wednesday, November 5, 2014 ... management will hold a conference call at 7:30 a.m. ... 8:30 p.m., Beijing Time on November 6, 2014, to ...
(Date:10/30/2014)... MADRID , October 30, 2014 ... hidrolizada con probiótico LGG contribuye a adquirir tolerancia ... La alergia a la proteína de la leche ... lactantes y primera infancia. Hasta ahora, la APLV ... dieta. Recientemente, se ha demostrado que es posible ...
Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3China Biologic to Report Third Quarter 2014 Financial Results 2Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3
... of data from more than 12,000 people with cystic fibrosis ... infection in the Cystic Fibrosis Foundation,s Patient Registry shows that ... associated with a 21% reduction in mortality in the following ... North American Cystic Fibrosis Conference (NACFC) in Baltimore, Maryland, sponsored ...
... Bionovo, Inc. (Nasdaq: BNVI ) today announced ... discussing new classes of estrogen receptor modulating drugs with ... in the most recent edition of Current Opinion ... Specific Target Genes and Biological Responses by Estrogen Receptor ...
Cached Medicine Technology:Analysis Shows Novartis Drug TOBI® Associated With Reduced Mortality in Cystic Fibrosis Patients With Common Lung Infection 2Analysis Shows Novartis Drug TOBI® Associated With Reduced Mortality in Cystic Fibrosis Patients With Common Lung Infection 3Analysis Shows Novartis Drug TOBI® Associated With Reduced Mortality in Cystic Fibrosis Patients With Common Lung Infection 4Analysis Shows Novartis Drug TOBI® Associated With Reduced Mortality in Cystic Fibrosis Patients With Common Lung Infection 5Bionovo Announces Publication Describing Potential Estrogen Receptor Modulating Drugs for Treating Menopausal Conditions 2Bionovo Announces Publication Describing Potential Estrogen Receptor Modulating Drugs for Treating Menopausal Conditions 3Bionovo Announces Publication Describing Potential Estrogen Receptor Modulating Drugs for Treating Menopausal Conditions 4
... is enzyme immunoassay kit for the ... concentration in serum. Enzyme immunoassay (EIA) ... many protein hormones in body fluids ... rapid and specific assay. This enzyme ...
SHIONORIA BNP,is a reagent used in the measurement of blood BNP. The blood BNP test allows accurate estimation of coronary functions....
... method for the semi-quantitative determination of ... human serum. The results of the ... an aid in the diagnosis of ... with elevated anti-neutrophil cytoplasmic antibodies (P-ANCA) ...
... The determination of Ang ... in monitoring the pharmacological effect ... variety of angiotensin converting enzyme ... II receptor antagonists as well ...
Medicine Products: